Assembly Biosciences CEO and leadership

Uri Lopatin, MD was a co-founder and the Chief Medical Officer of Assembly Pharmaceuticals (2012) and CMO/VP R&D for Assembly Biosciences (f\k\a Ventrus Bioscience), which reverse merged with Assembly Pharmaceuticals in 2014. He has helped Assembly raise over $300M to move their first 2 generations of novel therapeutics into global phase 1 and phase 2 clinical studies. Uri has held clinical and translational science roles at Schering Plough, Roche, and Gilead Sciences. He previously received his medical training at UMDNJ-NJMS, UW, NYU and the NIH. He lives with his wife and son in San Francisco.

William Delaney, PhD joined Assembly as Chief Scientific Officer, Virology in May 2020. Prior to joining Assembly, he most recently served as Executive Director, Biology at Gilead. During his 20-year career at the company, he headed the Viral Hepatitis & Herpes Discovery Biology Groups and served as the Research Therapeutic Area Head for HBV. He began his career as a Research Scientist, Clinical Virology at Gilead and later transitioned into Drug Discovery where he held positions of increasing responsibility. Over the course of his career, he has contributed to the development of several marketed products, including Hepsera®, Viread®, and Vemlidy® for HBV and Sovaldi®, Harvoni®, Epclusa®, and Vosevi® for HCV. He earned a BS in Biotechnology from the University of Delaware and a PhD in Cell and Molecular Biology from the Penn State College of Medicine. In addition, he was a Postdoctoral Fellow at the Victorian Infectious Diseases Reference Laboratory (VIDRL), Department of Research & Molecular Development.

Jason Okazaki joined Assembly as Chief Legal and Business Officer in March 2020. Most recently, he served as Senior Vice President, Legal and Assistant Secretary at Gilead Sciences. During his 14-year career there, he built and led a global legal team that supported the Company’s operations in the U.S., Asia and Latin America and advised on corporate governance and SEC reporting matters. In addition, he led the structuring and legal execution of all of Gilead’s acquisitions, strategic collaborations and licensing deals since 2006. Previously, he worked for six years with Skadden, Arps, Slate, Meagher & Flom LLP in the firm’s mergers and acquisitions and corporate finance practices. Mr. Okazaki earned a BA in Economics from Stanford University and a JD from the UC Hastings College of the Law. He is a member of the State Bars of California and New York.

Uri Lopatin, MD was a co-founder and the Chief Medical Officer of Assembly Pharmaceuticals (2012) and CMO/VP R&D for Assembly Biosciences (f\k\a Ventrus Bioscience), which reverse merged with Assembly Pharmaceuticals in 2014. He has helped Assembly raise over $300M to move their first 2 generations of novel therapeutics into global phase 1 and phase 2 clinical studies. Uri has held clinical and translational science roles at Schering Plough, Roche, and Gilead Sciences. He previously received his medical training at UMDNJ-NJMS, UW, NYU and the NIH. He lives with his wife and son in San Francisco.